Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Atomo Diagnostics Ltd. ( (AU:AT1) ).
Atomo Diagnostics has released a prospectus for a security purchase plan offering up to 30,303,030 new shares at $0.033 each, with one free unlisted option attached for every two shares, aiming to raise up to $1 million before costs from eligible shareholders. The company will also offer an equivalent number of shares and options as a shortfall facility if the plan is not fully subscribed, a move that underscores its reliance on equity funding and signals the speculative nature of the investment, with investors warned they may lose some or all of their capital.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is a medical diagnostics company that develops and supplies rapid diagnostic test devices, with a focus on easy-to-use, point-of-care solutions. The company targets healthcare providers and programs seeking accurate, affordable, and rapid testing technologies in clinical and decentralized settings.
Average Trading Volume: 2,349,202
Technical Sentiment Signal: Hold
Current Market Cap: A$25.23M
See more insights into AT1 stock on TipRanks’ Stock Analysis page.